Insulin problems reduced by Curcumin if not also take Omega-3 – RCT

Curcumin and/or omega-3 polyunsaturated fatty acids supplementation reduces insulin resistance and blood lipids in individuals with high risk of type 2 diabetes: a randomised controlled trial

Lipids in Health and Disease 201918:31; https://doi.org/10.1186/s12944-019-0967-x

Rohith N. Thota, Shamasunder H. Acharya and Manohar L. Garg

* Curcumin helps many health problems * Large amounts of curcumin might activate the Vitamin D receptor – Dec 2010 * ALS reduction far more likely if take Curcumin, Luteolin, CBD, Omega-3, or Vitamin D etc – April 2018 * Alzheimer’s may be treated by vitamin D3 and curcumin – March 2012 * Natural Ways to Increase Calcitriol and Activate The Vitamin D Receptor Gene – Oct 2017 * [Curcumin extract for prevention of type 2 diabetes](https://nutritionfacts.org/2018/07/03/the-spice-proven-to-benefit-prediabetes/?utm_source=NutritionFacts.org&utm;_campaign=116f57ac48-RSS_BLOG_WEEKLY&utm;_medium=email&utm;_term=0_40f9e497d1-116f57ac48-25209481&mc;_cid=116f57ac48&mc;_eid=b95641625a) July 2018 - includes video summary * "After nine months of treatment, 16 % of subjects in the placebo group went on to get full-blown diabetes. " * :How many in the curcumin group? None ." Overview Diabetes and vitamin D contains the following summary {include}

Download the PDF from VitaminDWiki

image

Background

Lowering insulin resistance and dyslipidaemia may not only enhance glycaemic control but also preserve the β-cell function, reducing the overall risk of developing type 2 diabetes (T2D). The current study was aimed to evaluate the effects of curcumin and/or long-chain omega-3 polyunsaturated fatty acids (LCn-3PUFA) supplementation on glycaemic control and blood lipid levels in individuals at high risk of developing T2D.

Methods

This was a 2 × 2 factorial, randomised, double-blinded, placebo-controlled study.

Participants were allocated to either

  • double placebo (PL) or

  • curcumin plus placebo matching for LCn-3PUFA (CC), or

  • LCn-3PUFA plus placebo matching for curcumin (FO), or

  • curcumin plus LCn-3PUFA (CC-FO)

for twelve weeks. Primary outcome of the trial was glycaemic indices (HbA1C, fasting glucose and insulin). Insulin resistance and sensitivity is measured using homeostatic model assessment model.

Results

A total of sixty-four participants (PL, n = 16; CC, n = 15; FO, n = 17, CC-FO, n = 16) were included in the final analysis. Post-intervention, HbA1c and fasting glucose remained unchanged across all the groups. Insulin sensitivity was significantly improved in the CC supplemented group (32.7 ± 10.3%) compared to PL (P = 0.009). FO and CC-FO tended to improve insulin sensitivity by 14.6 ± 8.5% and 8.8 ± 7.7% respectively, but the difference did not reach significance. Triglyceride levels were further increased in the PL (26.9 ± 7.4%), however, CC and CC-FO supplementation reduced the triglycerides, FO resulted in the greatest reduction in triglycerides (− 16.4 ± 4.5%, P < 0.001).

Conclusion

Reduction in insulin resistance and triglycerides by curcumin and LCn-3PUFA appears to be attractive strategies for lowering the risk of developing T2D. However, this study failed to demonstrate complimentary benefits of curcumin and LCn-3PUFA on glycaemic control.

Trail registration ACTRN12615000559516.